Continuous subcutaneous insulin infusion treatment was effective in lowering HbA1C levels in children with type 1 diabetes, with improvements sustained at 48 months, according to a study presented at the annual meeting of the Pediatric Academic Societies. CSII treatment lacks cost-effectiveness but is safe and well-tolerated compared with multiple daily injections, researchers said.

Full Story:
Endocrine Today

Related Summaries